There is effect of Carbimazole on oxidative stress with Hyperthyroidism. To assess the oxidative stress and total antioxidant capacity in hyperthyroid patient and evaluate the effect of Carbimazole on oxidative stress and total antioxidant status. Case series study design. The study was conducted in departments of general surgery outpatient private clinic of and AL-Jumhori teaching hospital. The study period between Dec .1st, 2020 and April.1st, 2021. Thirty patients newly diagnosed with hyperthyroidism and thirty healthy volunteers as control group were participated in the study. Malondialdehyde (MDA) and total antioxidant status (T-AOC) were measured control group and also measured in patients with hyperthyroidism before and after taking Carbimazole therapy for two months duration. Indicated an increase in mean serum MDA level (4.74 ± 3.62 ng/ml), also there was a significantly lower level of T-AOC (6.72 ± 3.08 U/ml) in patients with HTH disorder before therapy in comparison with the control group (1.83 ± 0.47 ng/ml), (10.38 ± 2.32 U/ml), respectively. After two months of antithyroid therapy (Carbimazole), there was a significant reduction in MDA levels (2.51 ± 1.99 ng/ml),(P-value = 0.001) and a significant increase in serum T-AOC level (8.57 ± 3.09 U/ml), (P-value = 0.001) in comparison to their values before therapy. The present study demonstrated that hyperthyroid patients have increased level of malondialdehyde and decreased levels of total antioxidants capacity than the control group while hyperthyroid patients treated with Carbimazole for two months have decreased level of MDA and increased levels of T-AOC than their levels before treatment. This result may give a new insight that Carbimazole may exhibit its effect in the management of hyperthyroidism by acting as an antioxidant.

Objective; of the this study was to investigate the effect of sitagliptin on blood glucose ,oxidative stress and total antioxidant status (TAS) in people with type 2 diabetes mellitus. Design: Case-control studySelection; The patients were selected from main diabetic clinics in al-Wafaa' Diabetic Clinic and from private clinics in Mosul city during the period from 1st of November 2020 to the 30 t h April 2021.Methods; It was conducted randomly 60 patients (32 males , 28 females ) of Non-insulin diabetes mellitus , who were already on routine anti-diabetic therapy ,those separated into 2groups. First Group : included 30 patients( 17 males,13 females) of T2DM treated with oral metformin alone Second group : included 30 patients( 15 males ,15 females) of T2DM treated with combination of Sitagliptin + metformin for at least 3 months , measured fasting plasma glucose, glycosylated hemoglobin another 30 healthy subjects , age ,sex matched with the patients, were considered as a control groups . Malondialdehyde (MDA) and Total antioxidant status (TAS) were measured in all groups Results; of this study, serum MDA levels were found high and TAS concentrations was lower in diabetic patients of both groups than the healthy control, the combination of sitagliptin + metformin caused significant reduction( P-value > 0.05) in the level of glycosylated hemoglobin ( HBA1c ) and malondialdehyde (MDA) in comparison with group that received metformin monotherapy ,as well as ,non-significant change in fasting blood group( FBG) and total antioxidant status (TAS )in both groups As a conclusion of the present study sitagliptin can attenuated MDA in patient with NIDDM and greater reduction in serum level of HBA1c than the use of metformin monotherapy.